Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 6Neoplasms 4Lymphoma, Follicular 4Lymphoma, Non-Hodgkin 3Neoplasms, Plasma Cell 2Multiple Myeloma 2Melanoma 2Leukemia 2Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Hodgkin Disease 1Healthy Volunteer 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × keyhole-limpet hemocyanin × Clear all
NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡